NasdaqGS:PCVXBiotechs
Vaxcyte (PCVX) Valuation Check After OPUS Phase 3 Milestone for Next-Gen Pneumococcal Vaccine
Vaxcyte (PCVX) just crossed a major clinical milestone by dosing the first participants in its OPUS Phase 3 trial for VAX-31, a next generation pneumococcal vaccine candidate aligned with FDA expectations.
See our latest analysis for Vaxcyte.
The OPUS Phase 3 start comes after a volatile stretch, with the latest share price at $44.34 and a roughly 44% 3 month share price return contrasting with a much weaker 1 year total shareholder return. This suggests near term momentum is rebuilding as...